Historic vote heralds one of the largest ever public investments in neuroscience and neurodegenerative disease research.
This week, voters in Texas overwhelmingly approved a ballot measure that allocates a staggering $3 billion in state funds to brain health research over the next decade. With more than two-thirds of voters in favor, the approval of “Proposition 14” reportedly represents the largest state-level financial commitment to neurodegenerative disease research in US history.
The measure will support the Dementia Prevention and Research Institute of Texas (DPRIT), a fund created earlier this year designed to accelerate discoveries in neuroscience and neurodegenerative diseases such as Parkinson’s and Alzheimer’s. DPRIT will serve as a key mechanism for implementing Proposition 14, focusing on expanding clinical trial access, building the brain health workforce and strengthening the state’s capacity for neuroscience research and commercialization.
The inclusion of Parkinson’s disease as a priority area for funding followed testimony from Texans living with the condition and advocacy from local and national organizations, including The Michael J Fox Foundation for Parkinson’s Research (MJFF). The foundation claims that Parkinson’s cases in Texas have more than doubled in recent years, with an annual economic cost exceeding $3.6 billion.
“With the passage of Proposition 14, Texas is setting a national example for public investment in science to help deliver the breakthroughs people living with Parkinson’s urgently deserve,” said MJFF policy head Dan Feehan. “Other states and the federal government should look to Texas as a model for bold, forward-looking investment in public health.”
Patient advocates and research organizations argued that targeted investment could not only improve health outcomes but also yield substantial savings for the healthcare system and help maintain workforce participation among affected individuals.
“As someone who lives with Parkinson’s and cares for loved ones who also face this disease, I’ve seen how powerful it is when our community comes together to push for change,” said East Texas resident and movement disorder specialist María L De León. “The passage of Proposition 14 proves that collective advocacy can bring hope, progress and the promise of a better future for families like mine at home in Texas and around the world.”
While most attention is given to federal policy, Texas has once again demonstrated the significant power the US state system wields to influence longevity through legislative action. Earlier this year, Montana enacted a groundbreaking law that expands access to experimental longevity therapies well beyond previous “Right to Try” frameworks, now enabling clinics to provide Phase 1-passed experimental drugs to all residents, not just terminally ill patients.
The new Texas initiative draws its framework from the state’s earlier success with the Cancer Prevention and Research Institute of Texas (CPRIT), which has invested billions in oncology research. Like CPRIT, the new fund will be governed by an oversight commission and allocate grants through a competitive process aimed at supporting high-impact research, infrastructure and recruitment of top investigators.
DPRIT funds will be distributed over ten years to support basic and translational science, as well as partnerships that promote innovation across the state. It is expected the fund will accelerate the growth of neuroscience-focused startups, and foster closer collaboration between academic centers, federal agencies and private-sector biotechnology firms.
